Forian Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Forian Inc. performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Think of Forian as a "data factory." They take messy, disconnected information—like medical claims and pharmacy records—and clean it up. They turn this into useful intelligence for the healthcare and financial industries.

They operate like the "Netflix of data." Most of their revenue comes from subscription contracts lasting 12 to 36 months. They provide ongoing insights that help companies track patient journeys and drug effectiveness. Their main product, Forian Data, aggregates information from over 300 million patients, which is highly valuable to drug makers and investors.

2. Financial performance: The 2025 Snapshot

Forian is growing, but they are still spending more than they make.

• Revenue: They brought in $30.3 million in 2025, up 50% from $20.2 million in 2024. This growth came from the Kyber acquisition and a 15% increase in contract values for their top clients.
• Profitability: The company is narrowing its losses, moving from a $3.8 million loss in 2024 to a $2.9 million loss in 2025. They have successfully kept expense growth lower than revenue growth.
• Profit Margins: Gross margin—the money left after paying the direct costs of acquiring data—shifted from 64% in 2024 to 53% in 2025. This reflects the higher costs associated with securing proprietary, high-quality datasets.

3. Major wins and strategic moves

• The "Data Factory" Advantage: By cleaning massive datasets, they save clients time, allowing them to process information 40% faster than they could on their own.
• Expanding the Customer Base: They are successfully moving beyond healthcare. They now sell data to hedge funds for market analysis, with non-healthcare revenue segments growing 12% this year.
• Corporate Housekeeping: In early 2026, they moved their legal home to Maryland to align with more favorable corporate laws.

4. Financial health

• No Dividends: The company reinvests every dollar into research and sales to fuel growth. Your return depends entirely on the stock price rising.
• "Emerging Growth" Status: By utilizing this status, they save $500,000 annually in accounting costs, though this results in less auditor oversight than a typical blue-chip stock.
• Cash Position: At the end of 2025, they held $8.2 million in cash, providing an estimated 18–24 months of runway at their current spending rate.

5. Key risks

• The "Data Supply" Problem: Forian rents their data rather than owning it. A major supplier, responsible for 20% of their data, is leaving the business by late 2026. Replacing this source could impact profit margins by 5–8%.
• Accounting Flaws: They are currently upgrading their software to address previous flaws in tracking revenue from complex contracts. Until the new system is fully proven, the risk of accounting errors remains.
• Dilution: They have authorization to sell up to $50 million in new stock. If they choose to do this to fund growth or cover losses, it will increase the number of shares and reduce your ownership percentage.

6. Future outlook

Forian is betting that "data is king." They aim to be the go-to source for proving that drugs work in the real world, helping drug makers justify prices and meet regulations. Their 2026 goal is to integrate AI to automate data cleaning, which they expect will improve profit margins.

---

Investor Takeaway: Forian is a high-growth, speculative play. They are successfully expanding their revenue and customer base, but their path to profitability depends on managing data supply costs and successfully transitioning to new accounting software. If you are considering an investment, keep a close eye on their cash runway and their ability to replace key data suppliers without hurting their margins.